Continued strong growth and resolution to distribute Transplantation
Group, including discontinuing operations
· Sales growth was 17 percent in local currency. Sales amounted to SEK 97 (85)
million, corresponding to an increase of 14 percent in SEK.
· Sales growth within Fertility was 16 percent in local currency and 13
percent in SEK. Sales growth within Transplantation was 23 percent in local
currency and 22 percent in SEK.
· Operating income (EBIT) amounted to SEK 13 (14) million. One-time expenses
of SEK 5 million were charged against operating income ahead of the setting up
of Xvivo as an independent listed company. Excluding these expenses, operating
income amounted to SEK 18 (14) million, corresponding to an operating margin of
18 (17) percent.
· Net income amounted to SEK 8 (10) million, which gave earnings per share of
SEK 0.43 (0.49).
· Application for sales approval of STEEN Solution™ in USA submitted to the US
Food and Drug Administration, FDA.
· After closing day Vitrolife completed the acquisition of Cryo Management
Ltd, one of the world’s leading players within time-lapse for IVF, based in
· A resolution was adopted at the Extraordinary General Meeting of
shareholders in September to distribute the transplantation business to the
shareholders in October, and this business is thus reported as discontinuing
· After the resolution had been adopted to distribute Vitrolife’s
transplantation business, Vitrolife’s Board set up new financial objectives for
the company after closing day.
January - September
Group, including discontinuing operations
· Sales growth was 16 percent in local currency. Sales amounted to SEK 306
(261) million, corresponding to an increase of 17 percent in SEK.
· Sales growth within Fertility was 16 percent in local currency and 17
percent in SEK. Sales growth within Transplantation was 20 percent in local
currency and 23 percent in SEK.
· Operating income (EBIT) amounted to SEK 45 (37) million, corresponding to an
increase of 21 percent. The operating margin was 15 (14) percent.
· Income before tax amounted to SEK 44 (41) million. Net income amounted to
SEK 31 (29) million, which gave earnings per share of SEK 1.58 (1.45).
· The cash flow from operating activities was SEK 40 (29) million.
November 1, 2012
VITROLIFE AB (publ)
Queries should be addressed to:
Thomas Axelsson, CEO, tel +46 31 721 80 01
Mikael Engblom, CFO, tel +46 31 721 80 14
Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on
November 1, 2012 at 8:30 a.m.
This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
Vitrolife is a global biotechnology/medical device Group that has business
activities within the areas of fertility and transplantation. The Fertility
product area works with nutrient solutions (media), cryopreservation products
and advanced consumable instruments such as needles and pipettes, for the
treatment of human infertility. There is also business to enable the use and
handling of stem cells for therapeutic purposes. The Transplantation product
area works with solutions and systems to evaluate and maintain organs outside
the body in order to select usable organs and keep them in optimal condition
while waiting for transplantation.
Vitrolife today has approximately 220 employees and its products are sold in
almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there
are offices in USA, Australia, France, Italy, United Kingdom, China and Japan.
The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
Tel: 46 31 721 80 00. Fax: 46 31 721 80 90. E-mail: email@example.com. Website:
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
2321 Rosecrans Avenue.
El Segundo, CA 90245 Phone: (800) 307-6627 Fax: (800) 307-3567
25 Basinghall Street,
London EC2V 5HA
UK Phone: +1 866-465-8454